Von Eschenbach Disappointed With Critical Path Progress
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Commissioner tells Maryland biotech audience he wants FDA to be a bridge rather than a barrier to life science advances.
You may also be interested in...
Gene Logic To Share Genomic Data With FDA For Critical Path Initiative
Voluntary collaboration will help FDA develop quality standards for submission of microarray data.
FDA To Provide Updates On Agency Involvement In Critical Path Projects
Agency opportunities list highlights 76 “scientific projects” that could modernize the medical product development process.
Formycon And Bioeq Offer Ranibizumab Update
Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: